Table: Peptidream -Q1 group results (IFRS)
May 13 (Reuters)-
Peptidream Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Mar 31, 2026 Mar 31, 2025 Dec 31, 2026
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 4.76 4.23 32.00
(+12.6 pct) (+0.2 pct) (+72.8 pct)
Operating loss 1.14 loss 1.37 4.60
Pretax loss 1.20 loss 1.43 4.30
Net loss 854 mln loss 1.03 3.00
EPS Basic loss 6.62 yen loss 7.97 yen
EPS Diluted loss 6.62 yen loss 7.97 yen
Ann Div NIL NIL
-Q2 Div NIL NIL
-Q4 Div NIL NIL
NOTE - Peptidream Inc..
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4587.T
Recent news on PeptiDream
See all newsTable: Peptidream 6-MTH group results (IFRS)
Brief: Peptidream Inc. - Initiation Of Phase 1 Clinical Trial By Novartis Marks Milestone For Peptidream
Brief: PeptiDream Announces First Dosing Of 64cu-Pd-29,875 In Gastric Cancer Patients
Table: Peptidream -Q1 group results (IFRS)
Brief: Peptidream Announces The Initiation Of Phase 1 Clinical Trial By Its Collaboration Partner